Subscriber Content Preview | Request a free trialSearch  


Reverse merger market shrank in fourth quarter

Despite the decline in deals, reverse merger companies raised more capital. Continue reading

Skilled Healthcare hunts for small deals after merger

After Genesis Healthcare deal closes, Skilled will focus on short stay facility acquisitions. Continue reading

Five developments to watch as activism gains steam

With the economy slowly recovering in 2014, activist investors had a field day. So did advisers to companies fighting off their most vocal investors, or those concerned that an activist might put in an appearance. Continue reading

Mylan ex-CEO, Glass Lewis debate proxy adviser power

Glass Lewis to provide background info to 250 companies before distributing recommendations. Continue reading

Johnson & Johnson makes $835M deal with Isis

By investing in Isis Pharmaceuticals, the pharmaceutical giant, through its Janssen unit, expands its commitment to antisense drug treatment programs. Continue reading

Insurgencies by the numbers

Dissident shareholders went big in 2014: Bigger companies were targeted, funds under management expanded rapidly and insurgents teamed up more frequently than ever before. That dramatic story is reflected in the statistics. Continue reading

Coming soon: Big deals, bigger busts

Finally! Boldface buyouts, blockbuster mergers and some old LBO busts on the way in 2015. Here's a look at some of the themes and headlines likely to dominate the next 12 months. Continue reading

Allergan's $66 billion Actavis deal still a win for Pershing

Valeant says it can't justify $219 a share offer to shareholders. Continue reading

Pfizer strikes immuno-oncology pact with Merck

The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards. Continue reading

Activists find help in the shadows

Companies have used private detectives for years. Now, dissident shareholders are hiring their own gumshoes. With everybody watching everybody else, at least one group wins: The investigation firms. Continue reading

Ackman launches activist campaign at Zoetis

Investors will look for response from Zoetis on its investor day scheduled for Nov. 18. Continue reading

Intercept seen as poster-boy for possible biotech bubble

The stock remains high despite concerns about an old research scandal. Continue reading

Meet the journalists

Jim Cramer's 2013 M&A predictions

The Founder of and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!